Prescribed with gusto despite “uncertain” benefitsBMJ 2012; 344 doi: https://doi.org/10.1136/bmj.e2919 (Published 24 April 2012) Cite this as: BMJ 2012;344:e2919
- Patrick Holmes, general practitioner/locality GP lead
- 1Darlington Clinical Commissioning Consortia, Felix House Surgery DL2 1AA, UK
Within two years of their entrance into the UK market, dipeptidyl peptidase-4 (DDP-4) inhibitors had grabbed a 5% market share of the overall spend on commonly prescribed oral hypoglycaemic agents (data from the NHS Prescription …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial